Arrevus Overview

  • Year Founded
  • 2015

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 4

Employees

  • Latest Deal Type
  • Grant

  • Financing Rounds
  • 12

  • Investments
  • 2

Arrevus General Information

Description

Operator of a biotechnology company intended to develop antimicrobial peptide chaperone-protein inhibitors to eliminate the threat of antibiotic resistance. The company offers antimicrobial peptide chaperone-protein inhibitors for the treatment of diseases for which antibiotic resistance has important clinical implications and for which few therapies exist, enabling healthcare companies to treat serious life-threatening diseases in patients and provide quality life to them.

Contact Information

Website
www.arrevus.com
Ownership Status
Acquired/Merged
Financing Status
Formerly PE-Backed
Corporate Office
  • 2443 Lynn Road
  • Suite 210
  • Raleigh, NC 27612
  • United States
+1 (301)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Acquirer
Aceragen (Acquired)
Vertical(s)
Life Sciences
Corporate Office
  • 2443 Lynn Road
  • Suite 210
  • Raleigh, NC 27612
  • United States
+1 (301)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Arrevus Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Arrevus‘s full profile, request access.

Request a free trial

Arrevus Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Operator of a biotechnology company intended to develop antimicrobial peptide chaperone-protein inhibitors to eliminate
Drug Discovery
Raleigh, NC
4 As of 2021

New York, NY
 

Barcelona, Spain
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Arrevus Competitors (13)

One of Arrevus’s 13 competitors is Volastra, a Venture Capital-Backed company based in New York, NY.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Volastra Venture Capital-Backed New York, NY
Ona Therapeutics Venture Capital-Backed Barcelona, Spain
Ability Pharma Private Equity-Backed Cerdanyola, Spain
Avalyn Pharma Formerly VC-backed Boston, MA
Genentech Formerly VC-backed South San Francisco, CA
You’re viewing 5 of 13 competitors. Get the full list »

Arrevus Patents

  • 11

    Total Documents Applications and Grants

  • Total Patents Families

  • 2

    Granted

  • Pending

  • Expiring in next 12 mo

Arrevus Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2020014642-A2 Antibacterial peptide monomers and combinations for co-therapy Inactive 12-Jul-2018
WO-2020014642-A3 Antibacterial peptide monomers and combinations for co-therapy Inactive 12-Jul-2018
US-20200323950-A1 Antibacterial peptides and combinations for co-therapy Inactive 18-Dec-2017
WO-2019126035-A1 Antibacterial peptides and combinations for co-therapy Inactive 18-Dec-2017
US-20170119793-A1 Compositions and methods for treating bone and joint infections Inactive 12-Jun-2014 A61K31/575
To view Arrevus’s complete patent history, request access »

Arrevus Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Arrevus Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Arrevus‘s full profile, request access.

Request a free trial

Arrevus Investments & Acquisitions (2)

Arrevus’s most recent deal was a Merger/Acquisition with Aceragen (Acquired). The deal was made on 25-Oct-2021.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Aceragen (Acquired) 25-Oct-2021 Merger/Acquisition Drug Discovery
Melinta Therapeutics (Fusidic Acid) 05-Feb-2019 Corporate Asset Purchase Buildings and Property
To view Arrevus’s complete investments and acquisitions history, request access »

Arrevus Exits (1)

Arrevus’s most recent exit was on 25-Oct-2021 from Aceragen (Acquired). The exit was categorized as .

Company Name Exit Date Exit Type Exit Size Status Buyers
Aceragen (Acquired) 25-Oct-2021 Completed
To view Arrevus’s complete exits history, request access »

Arrevus FAQs

  • When was Arrevus founded?

    Arrevus was founded in 2015.

  • Where is Arrevus headquartered?

    Arrevus is headquartered in Raleigh, NC.

  • What is the size of Arrevus?

    Arrevus has 4 total employees.

  • What industry is Arrevus in?

    Arrevus’s primary industry is Drug Discovery.

  • Is Arrevus a private or public company?

    Arrevus is a Private company.

  • What is Arrevus’s current revenue?

    The current revenue for Arrevus is .

  • How much funding has Arrevus raised over time?

    Arrevus has raised $1.7M.

  • Who are Arrevus’s investors?

    First Flight Venture Center, Life Science Venture Capital, and North Carolina Biotechnology Center have invested in Arrevus.

  • Who are Arrevus’s competitors?

    Volastra, Ona Therapeutics, Ability Pharma, Avalyn Pharma, and Genentech are some of the 13 competitors of Arrevus.

  • When was Arrevus acquired?

    Arrevus was acquired on 05-Apr-2023.

  • Who acquired Arrevus?

    Arrevus was acquired by Aceragen (Acquired).

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process